Lista de obras - Bruno Cassinat - Dominio Público Uruguay

A new variant t(6;15;17)(q25;q22;q21) in acute promyelocytic leukemia: fluorescence in situ hybridization confirmation.

artículo científico

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations

scientific article published on 12 February 2019

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet

artículo científico publicado en 2015

Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET.

artículo científico publicado en 2017

Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms

artículo científico publicado en 2014

Auer rods and differentiation in acute promyelocytic leukemia

Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer

artículo científico publicado en 2011

Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone

artículo científico publicado en 2016

Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?

artículo científico publicado en 2007

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

artículo científico publicado en 2015

Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma

scientific article published on 05 February 2007

Clonal Hematopoiesis and Atherosclerosis

artículo científico publicado en 2017

Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number.

artículo científico publicado en 2012

Co-expression and secretion of C3, the third component of complement and a C3-cleaving cysteine proteinase in a highly metastatic human melanoma cell line ⬇️

artículo científico publicado el 1 de julio de 1997

Coexistence of a myeloproliferative disorder and secondary polycythemia in the same patient

artículo científico publicado en 2012

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

artículo científico publicado en 2003

Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation

artículo científico publicado en 2019

Constitutive elevation of serum alpha-fetoprotein in Fanconi anemia

artículo científico publicado en 2000

DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

artículo científico publicado en 2005

Development of a real-time PCR assay for quantitative detection of Encephalitozoon intestinalis DNA

artículo científico publicado en 2003

Diagnosis of Fanconi anemia in patients with bone marrow failure

artículo científico publicado en 2009

Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?

artículo científico publicado en 2012

Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.

artículo científico publicado en 2018

Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features

scientific article published on 13 August 2018

Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation.

artículo científico publicado en 2017

Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways.

artículo científico publicado en 1995

Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders

artículo científico publicado en 2006

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090

artículo científico publicado en 2013

Evaluation of total PSA assay on vitros ECi and correlation with Kryptor-PSA assay

scientific article published on 01 January 2001

Exome analysis of treatment-related AML after APL suggests secondary evolution

scientific article published on 22 November 2018

Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.

artículo científico publicado en 2010

Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.

artículo científico publicado en 2005

Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response.

artículo científico publicado en 2006

From Noonan syndrome to juvenile myelomonocytic leukemia

artículo científico publicado en 2008

From guidelines to hospital practice: reducing inappropriate ordering of thyroid hormone and antibody tests

artículo científico publicado en 2000

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia

artículo científico publicado en 2018

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

artículo científico publicado en 2010

Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.

artículo científico publicado en 2010

HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.

artículo científico publicado en 2007

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

artículo científico publicado en 2006

Identification of JAK2 mutations in canine primary polycythemia.

artículo científico publicado en 2011

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

artículo científico publicado en 2003

Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera.

artículo científico publicado en 2018

In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia.

artículo científico publicado en 2013

Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay

artículo científico publicado en 2005

Interferon alfa therapy in CALR-mutated essential thrombocythemia.

artículo científico publicado en 2014

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone

artículo científico publicado en 2015

Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients

artículo científico publicado en 2010

Intermethod discordance for alpha-fetoprotein measurements in Fanconi anemia

scientific article published on 01 August 2001

International external quality assurance of JAK2 V617F quantification

scientific article published on 08 December 2018

Is the thrombopoietin assay useful for differential diagnosis of thrombocytopenia? Analysis of a cohort of 160 patients with thrombocytopenia and defined platelet life span.

artículo científico publicado en 2001

JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway

artículo científico publicado en 2012

Juvenile myelomonocytic leukaemia and Noonan syndrome.

artículo científico publicado en 2014

Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.

artículo científico publicado en 2015

Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.

artículo científico publicado en 2015

Live and let (MPN cells) die!

artículo científico publicado en 2012

Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes

artículo científico publicado en 2012

Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients

artículo científico publicado en 2013

Low incidence of CALR gene mutations in patients with cerebral venous thrombosis without overt chronic myeloproliferative neoplasm

scientific article published on 29 July 2015

Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients.

artículo científico publicado en 2015

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

scientific article published on 01 March 2020

Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials

artículo científico publicado en 2014

Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients.

artículo científico publicado en 2008

Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register.

artículo científico publicado en 2004

New chimeric RNAs in acute myeloid leukemia.

artículo científico publicado en 2017

New role for granulocyte colony-stimulating factor-induced extracellular signal-regulated kinase 1/2 in histone modification and retinoic acid receptor α recruitment to gene promoters: relevance to acute promyelocytic leukemia cell differentiation.

artículo científico publicado en 2011

Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls

artículo científico publicado en 2018

Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.

artículo científico publicado en 2012

PML-RARalpha ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL

artículo científico publicado en 2009

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

article

Pep34, a synthetic peptide whose sequence corresponds to the intracytoplasmic domain of the Epstein-Barr virus receptor (CR2, CD21), regulates human B lymphocyte proliferation triggered through CR2.

artículo científico publicado en 1995

Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation

artículo científico publicado en 2003

Pitfalls in CALR exon 9 mutation detection: A single-center experience in 571 positive patients

artículo científico publicado en 2020

Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group

article

Quantification of JAK2V617F mutation by next-generation sequencing technology.

artículo científico publicado en 2013

Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation.

artículo científico publicado en 2015

Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR

scientific article published on 01 February 2000

Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations

artículo científico publicado en 2020

Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway

artículo científico publicado en 2012

Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.

artículo científico publicado en 2016

Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.

artículo científico publicado en 2010

Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction

scientific article published on 12 July 2006

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

artículo científico publicado en 2018

Screening for G-CSF receptor mutations in patients with secondary myeloid or lymphoid transformation of severe congenital neutropenia. A report from the French neutropenia register

artículo científico publicado en 2004

Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study

artículo científico publicado en 2017

Serum carcinoembryonic antigen, cancer antigen 125, cancer antigen 15-3, squamous cell carcinoma, and tumor-associated trypsin inhibitor concentrations during healthy pregnancy

artículo científico publicado en 1998

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition

artículo científico publicado en 2022

Successful xenografts of AML3 samples in immunodeficient NOD/shi-SCID IL2Rγ−/− mice

artículo científico publicado en 2012

TET2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosis

artículo científico publicado en 2014

The JAK2 46/1 haplotype in splanchnic vein thrombosis.

artículo científico publicado en 2011

The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow

artículo científico publicado en 2006

The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder

artículo científico publicado en 2008

The V617F JAK2 mutation and the increase in platelet CD36 in essential thrombocythemia are unrelated events

artículo científico publicado en 2007

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

artículo científico publicado en 2008

The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders

artículo científico publicado en 2017

Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia

artículo científico publicado en 2008

Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia.

artículo científico publicado en 2002

Unexplained thrombocytosis: association of Baltimore polymorphism with germline MPL nonsense mutation.

artículo científico publicado en 2015

Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

artículo científico publicado en 2013

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).

artículo científico publicado en 2009

Yeast Assay Highlights the Intrinsic Genomic Instability of Human PML Intron 6 over Intron 3 and the Role of Replication Fork Proteins

artículo científico publicado en 2015

Lista de obras de Bruno Cassinat

A new variant t(6;15;17)(q25;q22;q21) in acute promyelocytic leukemia: fluorescence in situ hybridization confirmation.

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet

Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET.

Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms

Auer rods and differentiation in acute promyelocytic leukemia

Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer

Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone

Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma

Clonal Hematopoiesis and Atherosclerosis

Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number.

Co-expression and secretion of C3, the third component of complement and a C3-cleaving cysteine proteinase in a highly metastatic human melanoma cell line ⬇️

Coexistence of a myeloproliferative disorder and secondary polycythemia in the same patient

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation

Constitutive elevation of serum alpha-fetoprotein in Fanconi anemia

DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

Development of a real-time PCR assay for quantitative detection of Encephalitozoon intestinalis DNA

Diagnosis of Fanconi anemia in patients with bone marrow failure

Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?

Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.

Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features

Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation.

Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways.

Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090

Evaluation of total PSA assay on vitros ECi and correlation with Kryptor-PSA assay

Exome analysis of treatment-related AML after APL suggests secondary evolution

Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.

Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.

Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response.

From Noonan syndrome to juvenile myelomonocytic leukemia

From guidelines to hospital practice: reducing inappropriate ordering of thyroid hormone and antibody tests

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.

HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

Identification of JAK2 mutations in canine primary polycythemia.

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera.

In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia.

Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay

Interferon alfa therapy in CALR-mutated essential thrombocythemia.

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone

Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients

Intermethod discordance for alpha-fetoprotein measurements in Fanconi anemia

International external quality assurance of JAK2 V617F quantification

Is the thrombopoietin assay useful for differential diagnosis of thrombocytopenia? Analysis of a cohort of 160 patients with thrombocytopenia and defined platelet life span.

JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway

Juvenile myelomonocytic leukaemia and Noonan syndrome.

Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.

Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.

Live and let (MPN cells) die!

Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes

Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients

Low incidence of CALR gene mutations in patients with cerebral venous thrombosis without overt chronic myeloproliferative neoplasm

Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients.

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials

Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients.

Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register.

New chimeric RNAs in acute myeloid leukemia.

New role for granulocyte colony-stimulating factor-induced extracellular signal-regulated kinase 1/2 in histone modification and retinoic acid receptor α recruitment to gene promoters: relevance to acute promyelocytic leukemia cell differentiation.

Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls

Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.

PML-RARalpha ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

Pep34, a synthetic peptide whose sequence corresponds to the intracytoplasmic domain of the Epstein-Barr virus receptor (CR2, CD21), regulates human B lymphocyte proliferation triggered through CR2.

Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation

Pitfalls in CALR exon 9 mutation detection: A single-center experience in 571 positive patients

Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group

Quantification of JAK2V617F mutation by next-generation sequencing technology.

Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation.

Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR

Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations

Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway